扶正抑瘤方协同微波消融治疗肝癌的临床研究

目的探讨扶正抑瘤方协同微波消融治疗肝癌的临床应用价值。方法 60例肝癌患者采用随机数字表法分成对照组(30例)和治疗组(30例)。对照组单纯行微波消融治疗,治疗组于微波消融治疗后3天加用扶正抑瘤方,疗程6个月,治疗结束后对两组患者的近期客观疗效、肝功能、肝纤维化指标及细胞免疫功能进行统计学分析。结果治疗后治疗组肝功能、肝纤维化、细胞免疫功能等指标较对照组均有显著改善(P<0.05),治疗组CD4+(40.38±12.47)、CD4+/CD8+(1.49±0.41)较对照组(CD4+:28.19±6.59,CD4+/CD8:1.22±0.31)明显升高,治疗组6个月结节复发率(14.0%)较对照组(33.3%)显著降低(P<0.05)。结论扶正抑瘤方协同微波消融治疗肝癌可提高疗效,增强机体免疫力,改善肝功能及肝纤维化程度。

Clinical Study of Fuzheng Yiliu Recipe Combined with Microwave Ablation on Hepatocellular Carcinoma

Objective To explore the clinical value of Fuzheng Yiliu Recipe(FYR) combined with microwave ablation on hepatocellular carcinoma.Methods Sixty patients with hepatocellular carcinoma were randomly assigned to the control group and the treatment group according to the random digit table,30 in each group.Patients in the control group received microwave ablation therapy,while those in the treatment group received FYR three days after microwave ablation.The therapeutic course was 6 months.By the end of the treatment,the short-term objective therapeutic efficacy,the liver function,the hepatic fibrosis index,the cellular immune function were statistically analyzed between the two groups.Results The indices of the liver function,the hepatic fibrosis,and the cellular immune function were more significantly improved in the treatment group than in the control group(P<0.05).The CD+4 level and the ratio of CD+4/CD+8 of the treatment group were remarkably higher than those of the control group(40.38±12.47 vs 28.19±6.59,1.49±0.41 vs 1.22±0.31).The tubercle recurrence rate of the treatment group(14.0%,7/50) was significantly lower than that of the control group(33.3%,15/45) after 6 months of treatment(P<0.05).Conclusion FYR combined with microwave ablation could elevate the therapeutic efficacy,enhance the patients’ immunity,improve the liver function and the hepatic fibrosis degree.